Pioneering a paradigm shift in treating Alzheimer's and Parkinson's through neuropeptide preservation and replacement.
Peer-reviewed funding from two of the world’s leading dementia research organisations — validation of our scientific approach as we head into human trials.
Even drugs that successfully reduced plaques by nearly 70% showed no cognitive improvement — and direct amyloid blocking drugs actually accelerated decline.
The breakthrough insight: Alzheimer's and Parkinson's are driven by neuropeptide depletion, not accumulation. When soluble neuropeptide levels fall below a critical threshold, synapses fail and cognition collapses.
We restore what the brain needs.
Neuropep Therapeutics focuses on restoring synaptic function and recovering memory formation via two complementary approaches: protection of endogenous peptides in the CSF, and replacement via stable peptide analogues.
The brain isn't poisoned.
It's starving.
Decades of research targeting protein aggregation in neurodegenerative diseases have yielded limited clinical success. We believe this reflects a fundamental misunderstanding of disease mechanism.
Recent evidence suggests that certain neuropeptides previously thought to be pathogenic may actually serve critical physiological functions. Their depletion, rather than their accumulation, may drive disease progression.
Neuropep Therapeutics is developing a dual approach: protecting endogenous neuropeptides from degradation and developing novel peptide replacement therapeutics.
We're combining insights from evolutionary biology, clinical trial data, and preclinical research to address what we believe is the underlying pathophysiology of Alzheimer's and related conditions.
Addressing neurodegeneration at multiple stages — from prevention to potential reversal.
A novel oral monotherapy formulation — first to market for this specific approach — protecting endogenous neuropeptides from degradation. Derived from an FDA-approved therapeutic with established safety profile, our proprietary formulation represents new intellectual property with a de-risked development pathway.
Second-generation non-aggregating peptide analogues with novel structural modifications, enhanced brain penetration, and optimized stability. Neuropep Therapeutics is racing to become the first company to deliver a curative neuropeptide replacement therapy — safe, non-aggregating analogues that directly restore the synaptic function lost in Alzheimer's and Parkinson's disease.
Independent experts in Alzheimer's, Parkinson's, clinical informatics, and patient advocacy providing rigorous external validation of our platform thesis.
For investment inquiries and partnership opportunities. We welcome conversations with accredited investors at all stages.